Open AccessImmunotherapy and non-small cell lung cancers
Author(s) -
Letizia Laera,
Silvia Novello
Publication year - 2017
Publication title -
cancer breaking news
Language(s) - English
Resource type - Journals
ISSN - 2283-6594
DOI - 10.19156/cbn.2017.0052
Subject(s) - immunotherapy , lung cancer , medicine , oncology , pd l1 , cancer , lung , cancer research , treatment of lung cancer , immune system , cancer immunotherapy , immunology
Lung cancer is the leading cause of cancer mortality, and non-small cell lung cancer (NSCLC) accounts for more than 85% of all lung cancers. Immunotherapy has brought a paradigm shift to the treatment of NSCLC. Immune checkpoint inhibitors have emerged as one of the main new therapeutic options for patients with advanced NSCLC. This brief review focuses on analyzing the biological rationale and early clinical data available concerning immunotherapeutic strategies, and more specifically, programmed cell death-1 (PD-1) inhibitors and programmed cell death-ligand 1 (PD-L1) inhibitors.